The sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix has been highlighted in a long-term follow-up study. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than nine years, and vaccine efficacy (VE) against incident infection was 100%. This is the longest follow-up report for a licensed HPV vaccine. Visit www.landesbioscience.com/journals/vaccines/article/29532//a for ...Saturday 2 August 2014
Long-Term Follow-Up Highlights Sustained Efficacy, Immunogenicity, and Safety for GlaxoSmithKline's HPV Vaccine
The sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix has been highlighted in a long-term follow-up study. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than nine years, and vaccine efficacy (VE) against incident infection was 100%. This is the longest follow-up report for a licensed HPV vaccine. Visit www.landesbioscience.com/journals/vaccines/article/29532//a for ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment